Osteosarcopenia Revisited: From Mechanisms to Management

Clicks: 15
ID: 325957
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #27 of 122 articles by views in journal of bone and mineral research : the official journal of the american society for bone and mineral research

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 122 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Sarcopenia and osteoporosis are characterized by insufficient mass and function of skeletal muscle and bone, and often co-occur in older persons, a condition called osteosarcopenia. Loss of bone and skeletal muscle mass and function is driven by multiple risk factors that activate the hallmarks of aging. Recent genome-wide association studies in humans and animal models suggest pivotal roles for mitochondria, the nucleus, and nutrient anabolism, which are closely associated with the hallmarks of aging, as well as for osteokines and myokines, in the development of osteosarcopenia. Osteosarcopenia is associated with a higher risk of adverse outcomes, such as falls, fractures, depression, and frailty, and consequently with mortality. Diagnosis of osteosarcopenia involves various imaging techniques to assess bone mineral density and skeletal muscle mass, as well as assessments of physical performance or muscle function. Moreover, a comprehensive evaluation of medical history, medications, and laboratory data is important for identifying potential contributing factors and assessing risk. To manage and treat osteosarcopenia, a multimodal approach, such as exercise therapy, nutritional supplementation, and pharmacotherapies, is required. Future prospects include technological innovations such as artificial intelligence and the identification of novel biomarkers based on multi-omics analyses, which will help enhance early detection of this condition. Emerging drugs that positively regulate bone and muscle mass are under development and are expected to contribute to individually optimized care for osteosarcopenia.
Reference Key
openalex_W7203983922 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Takayoshi Sasako, Miguel Germán Borda, Marc Sim, Gustavo Duque
Journal journal of bone and mineral research : the official journal of the american society for bone and mineral research
Year 2026
DOI
10.1093/jbmr/zjag127
URL
https://doi.org/10.1093/jbmr/zjag127
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.